Longeveron (LGVN) Misses Q2 EPS by 4c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 11/4/2026

1. AMD
2. BKNG
3. AMGN
4. DOX
5. DUOL
6. ANET
7. SWKS
8. SPY
9. XYZ
10. FISV

Go back to Longeveron (LGVN) Misses Q2 EPS by 4c

Longeveron Inc. Provides Corporate Update and Reports Second Quarter 2022 Financial Results

August 12, 2022 8:00 AM EDT

Longeverons Phase 2a trial of Lomecel-B for patients with mild Alzheimers Disease proceeding on schedule, currently at 50% enrollment

Japanese Pharmaceuticals and Medical Devices Agency Accepts Amended Aging Frailty study design August 8, 2022, allowing the trial to begin

Top-line findings from the second phase of the Phase 1/2 HERA trial show that the primary endpoint for safety was met in the randomized placebo-controlled portion of the study

$27 million in cash, cash equivalents and short-term investments as of June 30, 2022, expected to be sufficient to fund operations into 2024

... More